KemPharm, Inc. – NASDAQ:KMPH

Add to watchlist

Market closed

Open in about 11 hours

+5.45%

month

+24.41%

quarter

-2.02%

year

Market Cap	200.47M
Enterprise value	158.03M

P/E	-6.38
EV/Sales	15.11
EV/EBITDA	-3.85
Price/Sales	19.16
Price/Book	2.33
PEG ratio	-0.14
EPS	N/A

Revenue	16.56M
EBITDA	-25.46M
Income	-28.15M
Revenue Q/Q	0.73%
Revenue Y/Y	54.49%

Profit margin	-397.24%
Oper. margin	-68.65%
Gross margin	96.72%
EBIT margin	-68.65%
EBITDA margin	-153.73%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

KemPharm, Inc. (NASDAQ:KMPH): Profit margin
Dec 2022	2.31M	-9.02M	-389%
Mar 2023	2.87M	-340	-0.01%
Jun 2023	8.47M	-5.08M	-60.02%
Sep 2023	2.89M	-14.04M	-485.15%

KemPharm, Inc. (NASDAQ:KMPH): Earnings per share (EPS)
2022-11-09	-0.28031	-0.1918
2022-12-31	-0.22405	-0.26156

KemPharm, Inc. (NASDAQ:KMPH): Debt to assets
Dec 2022	115529000	29.72M	25.73%
Mar 2023	106595000	35.19M	33.01%
Jun 2023	105518000	37.01M	35.08%
Sep 2023	138982000	71.51M	51.45%

KemPharm, Inc. (NASDAQ:KMPH): Cash Flow
Dec 2022	-4.46M	-63K	-257K
Mar 2023	-4.04M	-17.55M	-3.75M
Jun 2023	1.51M	0	0
Sep 2023	1.38M	0	0

KemPharm alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

KemPharm, Inc. (NASDAQ:KMPH): Employee count
Aug 2023	24
Sep 2023	24
Oct 2023	24
Nov 2023	24
Dec 2023	24
Jan 2024	24
Feb 2024	24
Mar 2024	24
Apr 2024	24
May 2024	24
Jun 2024	24
Jul 2024	24

KemPharm
Hedge Funds Holdings Q3 2022

21.97% -2.44%

of KMPH is owned by hedge funds

59 -6

hedge funds hold KMPH stock

6.53M -725.04K

shares is hold by hedge funds

KMPH hedge funds holdings changes

KemPharm, Inc. (NASDAQ:KMPH): Insider trades (number of shares)
Period	Buy	Sel
Jan 2023	10135	0
Mar 2023	31444	0
May 2023	13140	0
Jun 2023	600	0
Sep 2023	21000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	6 Sep 2023	CLIFTON R. LADUANE officer: CFO, Secretary & Treasurer officer: CFO, Secretary & Treas..	Common Stock	1,000	$4.96	$4,959
Purchase	6 Sep 2023	ANDERSON THOMAS director director	Common Stock	10,000	$4.88	$48,760
Purchase	5 Sep 2023	BODE JOHN B director director	Common Stock	10,000	$5.13	$51,330
Purchase	23 Jun 2023	WATTON COREY MICHAEL director director	Common Stock	275	$5.95	$1,636
Purchase	9 Jun 2023	WATTON COREY MICHAEL director director	Common Stock	325	$5.52	$1,794
Purchase	30 May 2023	WATTON COREY MICHAEL director director	Common Stock	400	$5.11	$2,042
Purchase	18 May 2023	BODE JOHN B director director	Common Stock	1,390	$5.04	$6,999
Purchase	18 May 2023	BODE JOHN B director director	Common Stock	300	$5.04	$1,512
Purchase	18 May 2023	BODE JOHN B director director	Common Stock	1,000	$5.04	$5,040
Purchase	18 May 2023	BODE JOHN B director director	Common Stock	4,759	$5.04	$23,985

Status	Patent	Filling date	Issue date
Application	Application LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM Filling date: 14 Dec 2021 Issue date: 31 Mar 2022	14 Dec 2021	31 Mar 2022
Application	Application DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM Filling date: 29 Nov 2021 Issue date: 24 Mar 2022	29 Nov 2021	24 Mar 2022
Application	Application D-AMPHETAMINE COMPOUNDS, COMPOSITIONS, AND PROCESSES FOR MAKING AND USING THE SAME Filling date: 13 Oct 2021 Issue date: 3 Mar 2022	13 Oct 2021	3 Mar 2022
Grant	Grant Utility: Levorphanol prodrugs and processes for making and using them Filling date: 12 Apr 2018 Issue date: 1 Feb 2022	12 Apr 2018	1 Feb 2022
Grant	Grant Utility: Dextrorphan prodrugs and processes for making and using them Filling date: 12 Apr 2018 Issue date: 4 Jan 2022	12 Apr 2018	4 Jan 2022
Grant	Grant Utility: D-amphetamine compounds, compositions, and processes for making and using the same Filling date: 29 Oct 2019 Issue date: 16 Nov 2021	29 Oct 2019	16 Nov 2021
Grant	Grant Utility: D-amphetamine compounds, compositions, and processes for making and using the same Filling date: 29 Oct 2019 Issue date: 5 Oct 2021	29 Oct 2019	5 Oct 2021
Application	Application COMPOSITIONS COMPRISING METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME Filling date: 26 Apr 2021 Issue date: 19 Aug 2021	26 Apr 2021	19 Aug 2021
Grant	Grant Utility: Compositions comprising methylphenidate-prodrugs, processes of making and using the same Filling date: 20 Sep 2019 Issue date: 1 Jun 2021	20 Sep 2019	1 Jun 2021
Grant	Grant Utility: Compositions comprising methylphenidate-prodrugs, processes of making and using the same Filling date: 20 Sep 2019 Issue date: 1 Jun 2021	20 Sep 2019	1 Jun 2021

KemPharm
Earnings Call Transcripts

Quarter	Transcript
Q3 2022 9 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 11 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 12 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 30 Mar 2022	Q4 2021 Earnings Call Transcript

KMPH earnings call transcripts

KemPharm
Executives

Insider	Age	Compensation
Dr. Travis C. Mickle Ph.D. (1973) Co-Founder, Pres, Chief Executive Officer & Director	52	$833,600
Dr. Sven Guenther (1972) Executive Vice President of R&D	53	$522,140
Mr. R. LaDuane Clifton CPA (1972) Chief Financial Officer, Sec. & Treasurer	53	$489,920
Mr. Richard W. Pascoe (1964) Executive Chairman	61	$42,190

KemPharm
Latest News

Monday, 27 February 2023
07:30	Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results	GlobeNewsWire
Friday, 3 February 2023
10:03	KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating	Seeking Alpha
Wednesday, 9 November 2022
22:01	KemPharm, Inc. (KMPH) Q3 2022 Earnings Call Transcript	Seeking Alpha
Thursday, 29 September 2022
12:47	KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study	Zacks Investment Research
Thursday, 1 September 2022
07:30	KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference	GlobeNewsWire
Thursday, 11 August 2022
19:57	KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Tuesday, 2 August 2022
07:30	KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference	GlobeNewsWire
Tuesday, 17 May 2022
13:32	KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M	Zacks Investment Research
Thursday, 12 May 2022
20:59	KemPharm, Inc. (KMPH) CEO Travis Mickle on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Wednesday, 20 April 2022
12:02	KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study	Zacks Investment Research
Wednesday, 30 March 2022
22:41	KemPharm, Inc. (KMPH) CEO Travis Mickle on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 10 March 2022
07:30	KemPharm to Report Fourth Quarter and Full-Year 2021 Results	GlobeNewsWire
Thursday, 20 January 2022
07:00	KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder	Benzinga
Wednesday, 12 January 2022
07:30	KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion	GlobeNewsWire
Friday, 19 November 2021
09:59	Implied Volatility Surging for KemPharm (KMPH) Stock Options	Zacks Investment Research
Wednesday, 10 November 2021
22:10	KemPharm's (KMPH) CEO Travis Mickle on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Wednesday, 3 November 2021
09:22	KemPharm to Report Third Quarter 2021 Results	GlobeNewsWire
Tuesday, 19 October 2021
07:30	KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market	GlobeNewsWire
Thursday, 23 September 2021
07:30	KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference	GlobeNewsWire
Thursday, 9 September 2021
07:30	KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference	GlobeNewsWire
Wednesday, 18 August 2021
16:45	KemPharm Appoints Tamara A. Seymour to Board of Directors	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 3 Feb 2023

KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating
Seeking Alpha 12 Jan 2023

C-Suite Transitions: Rite Aid CEO Departs Abruptly
Seeking Alpha 13 Apr 2021

Milestone Payment Confusion Has Created An Investment Opportunity In KemPharm

Frequently Asked Questions (FAQ)

When is KemPharm's next earnings date?

Unfortunately, KemPharm's (KMPH) next earnings date is currently unknown.
Does KemPharm pay dividends?

No, KemPharm does not pay dividends.
How much money does KemPharm make?

KemPharm has a market capitalization of 200.47M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 63.5% to 10.46M US dollars. KemPharm made a loss 41.54M US dollars in net income (profit) last year or -$0.26 on an earnings per share basis.
What is KemPharm's stock symbol?

KemPharm, Inc. is traded on the NASDAQ under the ticker symbol "KMPH".
What is KemPharm's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of KemPharm?

Shares of KemPharm can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are KemPharm's key executives?
KemPharm's management team includes the following people:
- Dr. Travis C. Mickle Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 52, pay: $833,600)
- Dr. Sven Guenther Executive Vice President of R&D(age: 53, pay: $522,140)
- Mr. R. LaDuane Clifton CPA Chief Financial Officer, Sec. & Treasurer(age: 53, pay: $489,920)
- Mr. Richard W. Pascoe Executive Chairman(age: 61, pay: $42,190)
Is KemPharm founder-led company?

Yes, KemPharm is a company led by its founder Dr. Travis C. Mickle Ph.D..
How many employees does KemPharm have?

As Jul 2024, KemPharm employs 24 workers.
When KemPharm went public?

KemPharm, Inc. is publicly traded company for more then 10 years since IPO on 16 Apr 2015.
What is KemPharm's official website?

The official website for KemPharm is kempharm.com.
Where are KemPharm's headquarters?

KemPharm is headquartered at 1180 Celebration Boulevard, Celebration, FL.
How can i contact KemPharm?

KemPharm's mailing address is 1180 Celebration Boulevard, Celebration, FL and company can be reached via phone at +32 19 39 34 16.

KemPharm, Inc.

kempharm.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.

+32 19 39 34 16

1180 Celebration Boulevard
Celebration, FL 34747

CIK: 0001434647
ISIN: US4884452065
CUSIP: 488445206